This was the only important key takeaway for medical imaging! As I have been mentioning it- AI has had the marketing component that’s been touted on social media, as the next “best thing”. I expect the madness to resume once the covid crisis wears off.
I have annotated an accompanying editorial which merits a longer argument.
Conclusions Few prospective deep learning studies and randomised trials exist in medical imaging. Most non-randomised trials are not prospective, are at high risk of bias, and deviate from existing reporting standards. Data and code availability are lacking in most studies, and human comparator groups are often small. Future studies should diminish risk of bias, enhance real world clinical relevance, improve reporting and transparency, and appropriately temper conclusions.